Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adare Pharmaceuticals and NLS Pharmaceutics Enter Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adare Pharmaceuticals and NLS Pharmaceutics Enter Collaboration

To develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adare Pharmaceuticals and NLS Pharmaceutics have formed a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

The collaboration will utilize Adare’s proprietary modified release technologies. The enhanced collaborative formulations are intended to deliver an effective pharmacokinetic profile, and are expected to improve patient compliance and disease management. MZD is a norepinephrine reuptake inhibitor previously approved by the U.S. Food and Drug Administration for the treatment of obesity.

“We are excited to enter this collaboration with NLS to develop new formulations for MZD, which will provide enhanced patient centric solutions for central nervous system disorders,” said Ajay Damani, vice president, pharmaceutical technologies, Adare. “Our expertise with product development and manufacturing of customized release and multiparticulate dosage forms makes this an ideal partnership for Adare.”

Alex Zwyer, chief executive officer and co-founder, NLS, said, “We believe that the partnership with Adare provides us with the expertise with respect to formulation that may help us to efficiently develop our product candidates. We value the experience Adare offers as part of our supply chain, and the new intellectual property applied to our product candidates. We anticipate success for both parties in this collaboration.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics